Reata Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch RETA and buy or sell other stocks, ETFs, and their options commission-free!About RETA
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
CEOJ. Warren Huff
CEOJ. Warren Huff
Employees—
Employees—
HeadquartersPlano, Texas
HeadquartersPlano, Texas
Founded2002
Founded2002
Employees—
Employees—
RETA Key Statistics
Market cap6.57B
Market cap6.57B
Price-Earnings ratio-57.67
Price-Earnings ratio-57.67
Dividend yield—
Dividend yield—
Average volume610.38K
Average volume610.38K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$172.46
52 Week high$172.46
52 Week low$21.83
52 Week low$21.83
Stock Snapshot
With a market cap of 6.57B, Reata Pharmaceuticals(RETA) trades at $172.36. The stock has a price-to-earnings ratio of -57.67.
On 2025-12-13, Reata Pharmaceuticals(RETA) stock opened at —, reached a high of —, and a low of —.
The Reata Pharmaceuticals(RETA)'s current trading volume is 0, compared to an average daily volume of 610.38K.
In the last year, Reata Pharmaceuticals(RETA) shares hit a 52-week high of $172.46 and a 52-week low of $21.83.
In the last year, Reata Pharmaceuticals(RETA) shares hit a 52-week high of $172.46 and a 52-week low of $21.83.
People also own
Based on the portfolios of people who own RETA. This list is generated using Robinhood data, and it’s not a recommendation.